Celularity Inc

GX Acquisition Corp. II, trading on Nasdaq under the ticker GXGX and sponsored by GX Capital, is a healthcare-focused special purpose acquisition company that completed its initial public offering in 2020. The company filed an 8-K with the SEC on January 8, 2021, disclosing material developments tied to its proposed business combination with Celularity Inc., a clinical-stage cellular medicine company developing off-the-shelf placenta-derived cell therapies. The filing marked a key milestone in the de-SPAC process, ultimately bringing Celularity into the public markets within the biotechnology and regenerative medicine sector. The merger was subsequently completed, with the combined company trading on Nasdaq under the ticker CELU. Sign up for full access on SpacDesk to explore GXGX's complete filing history, sponsor details, and transaction data alongside thousands of other SPACs.